Pharmaceutical development and specification of stereoisomers
- 1 September 1998
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 17 (6-7) , 917-924
- https://doi.org/10.1016/s0731-7085(98)00059-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Chiral drugs: The FDA perspective on manufacturing and controlPublished by Elsevier ,2002
- Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United StatesChirality, 1994
- Regulatory Requirements for Chiral DrugsDrug Information Journal, 1993
- Chiral Separations by High-Performance Liquid ChromatographyJournal of Chromatographic Science, 1992
- FDA'S policy statement for the development of new stereoisomeric drugsChirality, 1992
- Separation of drug enantiomers by HPLC using chiral stationary phases — A selective reviewChromatographia, 1990
- Enantioselective Aspects of Drug Action and Disposition: Therapeutic PitfallsJournal of Pharmaceutical Sciences, 1989
- Direct separation of drug enantiomers by high-performance liquid chromatography with chiral stationary phasesJournal of Chromatography B: Biomedical Sciences and Applications, 1988
- Influence of enantiomeric purity of a chiral selector on stereoselectivityJournal of Chromatography A, 1987
- Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overviewClinical Pharmacology & Therapeutics, 1986